GlassScriptPhysician profile
Rachel Reyes
NPI 1194298596
$8,672.93
in general payments reported to CMS, 2019-2025
24 companies · $1,005 in 2025
The $1,005 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,137 · 2022: $1,696 · 2023: $1,958 · 2024: $2,876 · 2025: $1,005.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,325 · Travel and Lodging: $1,515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,324.88 |
| Travel and Lodging | $1,514.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,539.29 | 2021-2025 | Tezspire, Fasenra, Airsupra |
| Intuitive Surgical, INC. | $1,525.73 | 2023-2024 | Da Vinci Surgical System |
| Glaxosmithkline, LLC. | $1,097.89 | 2021-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Genzyme Corporation | $748.25 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $668.75 | 2021-2025 | Ofev, Jascayd |
| Regeneron Healthcare Solutions, INC. | $432.49 | 2021-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $277.46 | 2023-2024 | Glassia, Cuvitru |
| Amgen INC. | $191.26 | 2022-2023 | Tezspire |
| Mylan Specialty L.P. | $179.48 | 2023-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $135.99 | 2021-2022 | |
| Genentech USA, INC. | $130.86 | 2022-2024 | Xolair |
| Grifols USA, LLC | $119.61 | 2021-2023 | Prolastin-C Liquid |
| Merck Sharp & Dohme LLC | $109.87 | 2021-2024 | Dificid, Zerbaxa, Recarbrio |
| Vifor Pharma, INC. | $93.82 | 2024 | Zemaira, Veltassa |
| Inspire Medical Systems, INC. | $80.48 | 2023 | Inspire |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $71.26 | 2022-2024 | Entre Plus, Flexitouch Plus |
| Verona Pharma, INC. | $63.98 | 2025 | Ohtuvayre |
| Advanced Respiratory, INC | $60.69 | 2021 | |
| Insmed, INC. | $38.98 | 2024-2025 | Arikayce |
| United Therapeutics Corporation | $30.59 | 2023 | Tyvaso |
| Gilead Sciences, INC. | $21.74 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $20.15 | 2021 | |
| Baxter Healthcare | $20.03 | 2024 | Hillrom - Monarch Airway Clearance System |
| Philips North America LLC | $14.28 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Reyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.